Tirzepatide Side Effects: Short and Long Term

The most common tirzepatide side effects are gastrointestinal — nausea, diarrhea, vomiting, constipation, dyspepsia, abdominal pain, and decreased appetite — which in clinical trials were typically mild-to-moderate, transient, and concentrated during dose escalation. Less common but more serious considerations include an FDA boxed warning for thyroid C-cell tumors (seen in rats), and warnings for pancreatitis, gallbladder disease, low blood sugar when combined with certain diabetes drugs, and dehydration-related kidney injury. This article summarizes what the prescribing information and major trials report. It is educational information, not medical advice.

What is tirzepatide, and is it FDA-approved?

Tirzepatide is a dual GIP/GLP-1 receptor agonist made by Eli Lilly. The same molecule is sold under two brand names. Mounjaro is FDA-approved as an adjunct to diet and exercise to improve blood sugar in adults with type 2 diabetes (initial U.S. approval 2022), per Mounjaro labeling. Zepbound, a separate FDA application, is FDA-approved for chronic weight management (November 2023) and for moderate-to-severe obstructive sleep apnea in adults with obesity (December 20, 2024), per Zepbound labeling. Both are FDA-approved branded tirzepatide.

This differs from compounded tirzepatide, which is not FDA-approved, is prescription only, and has not been evaluated by the FDA for safety, quality, or efficacy. The FDA-declared tirzepatide shortage is resolved — tirzepatide was removed from the shortage list effective October 2, 2024 (final declaratory order December 19, 2024), and the semaglutide shortage was declared resolved February 21, 2025, with compounding enforcement grace periods ending by May 2025. On April 30, 2026, the FDA proposed excluding semaglutide and tirzepatide from the 503B bulk drug substances list, a step that would further restrict outsourcing-facility compounding.

What are the most common short-term side effects of tirzepatide?

Across the prescribing information and trials, the short-term picture is dominated by GI symptoms that tend to appear or worsen when the dose increases, then ease over time. Importantly, the reported rates depend on the population studied — diabetes trials and obesity trials are not interchangeable.

In the FDA label’s pooled placebo-controlled type 2 diabetes trials, adverse reactions occurring in at least 5% of Mounjaro-treated patients followed a clear dose gradient (5/10/15 mg):

Adverse reaction	5 mg	10 mg	15 mg	Placebo
Nausea	12%	15%	18%	4%
Diarrhea	12%	13%	17%	9%
Decreased appetite	5%	10%	11%	1%
Vomiting	5%	5%	9%	2%
Constipation	6%	6%	7%	1%
Dyspepsia	8%	8%	5%	3%
Abdominal pain	6%	5%	5%	4%

Source: FDA Mounjaro prescribing information, pooled placebo-controlled type 2 diabetes trials (adverse reactions ≥5%).

A pooled analysis of SURPASS-1 to -5 (N=6,263 adults with type 2 diabetes; Patel et al., 2024) reported nausea in 12–24%, diarrhea in 12–22%, and vomiting in 2–13%, with events transient and mild-to-moderate. Notably, weight reduction in that analysis was similar in patients who did and did not report nausea, vomiting, or diarrhea — suggesting GI symptoms are not the mechanism behind weight loss.

Are tirzepatide side effects worse in people taking it for weight loss?

GI side effects were reported more often in the obesity population than in diabetes trials, so it is important not to blend the two. In the SURMOUNT-1 trial (adults with obesity or overweight without type 2 diabetes; NEJM 2022), nausea was reported by 24.6% / 33.3% / 31.0%, diarrhea by 18.7% / 21.2% / 23.0%, and vomiting by 8.3% / 10.7% / 12.2% at 5/10/15 mg, respectively — again mostly mild-to-moderate and concentrated during dose escalation. Adverse events led to discontinuation in 4.3% / 7.1% / 6.2% across those doses versus 2.6% on placebo.

So the “up to about 33% nausea” figure belongs to the obesity trial, while the “up to 18%” figure belongs to the diabetes label — different populations, not contradictory numbers. If you are weighing options, our overview of peptides for weight loss and the tirzepatide dosage chart add context on how titration is designed to limit these symptoms.

How does tirzepatide compare with semaglutide on side effects?

In the head-to-head SURPASS-2 trial (adults with type 2 diabetes on metformin; NEJM 2021), GI rates were broadly comparable between the two drugs. Tirzepatide (5/10/15 mg) ranges were nausea 17–22%, diarrhea 13–16%, and vomiting 6–10%, versus nausea 18%, diarrhea 12%, and vomiting 8% for semaglutide 1 mg. These semaglutide numbers are the SURPASS-2 comparator arm only; semaglutide (Ozempic/Wegovy) is a different molecule and is not interchangeable with tirzepatide.

GI event (T2D, SURPASS-2)	Tirzepatide 5–15 mg	Semaglutide 1 mg
Nausea	17–22%	18%
Diarrhea	13–16%	12%
Vomiting	6–10%	8%
Discontinuation (AEs)	6.0–8.5%	4.1%

Source: SURPASS-2 RCT, adults with type 2 diabetes (NEJM 2021).

What is the boxed warning on tirzepatide?

Tirzepatide carries an FDA boxed warning: in a 2-year carcinogenicity study, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors (adenomas and carcinomas) in rats at clinically relevant exposures. It is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, because the human relevance of the rodent finding has not been determined. This is a rat finding — it does not establish that tirzepatide causes thyroid cancer in people.

Because of this, tirzepatide is contraindicated in patients with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in patients with known serious hypersensitivity to the drug. Patients are counseled to report symptoms of a thyroid tumor — a neck mass, trouble swallowing, shortness of breath, or persistent hoarseness.

What serious side effects should I watch for?

The label’s warnings and precautions include several less-common but important risks:

• Acute pancreatitis — discontinue if suspected. In a systematic review and meta-analysis, the increased risk of acute pancreatitis was not statistically significant (RR 1.46, 95% CI 0.59–3.61).
• Acute gallbladder disease — reported by 0.6% of tirzepatide-treated patients versus 0% on placebo in pooled trials; the same meta-analysis found a significant increase in the gallbladder/biliary composite (RR 1.97, 95% CI 1.14–3.42).
• Hypoglycemia — tirzepatide alone has low intrinsic risk, but risk rises when combined with insulin or an insulin secretagogue (such as a sulfonylurea); the label advises considering a dose reduction of those agents.
• Acute kidney injury — usually from volume depletion when severe nausea, vomiting, or diarrhea causes dehydration. Staying hydrated and contacting a provider about persistent GI symptoms matters.
• Hypersensitivity — including reports of anaphylaxis and angioedema.
• Severe GI disease — caution in conditions such as gastroparesis.
• Diabetic retinopathy — patients with a history should be monitored.

What are the long-term side effects of tirzepatide (Mounjaro)?

Two long-term considerations come up most. First, muscle/lean-mass loss: as with most substantial weight loss, some of the weight lost is lean mass rather than fat. Peer-reviewed body-composition data (including SURPASS-3 MRI analyses) show lean-mass loss accompanies fat loss; emerging, non-peer-reviewed observational work suggests it may be somewhat greater than with semaglutide, though magnitudes vary by study. Resistance training and adequate protein intake are commonly recommended to help preserve muscle.

Second, weight regain after stopping. In the original SURMOUNT-4 randomized withdrawal trial (Aronne et al., JAMA 2024), mean weight reduction at week 88 was 25.3% with continued tirzepatide versus 9.9% after switching to placebo. In a later post hoc analysis of SURMOUNT-4 (JAMA Internal Medicine, 2026), among participants who had achieved at least 10% weight reduction during the lead-in, 82.5% (254 of 308) of those switched to placebo regained 25% or more of their lost weight by week 88. This underscores that, for chronic weight management, benefit is generally tied to ongoing use, and any plan should be provider-determined. Individual results vary, and no efficacy is guaranteed. If you are exploring metabolic and hormone-related options more broadly, our guide on signs you may need hormone replacement therapy may be a useful companion read.

Frequently asked questions

How long do tirzepatide side effects last?

In clinical trials, the most common GI side effects (nausea, diarrhea, vomiting) were generally transient and mild-to-moderate, occurring most often during dose escalation and tending to ease as the body adjusts. Persistent or severe symptoms should be discussed with a licensed provider.

Does tirzepatide cause thyroid cancer?

Tirzepatide caused thyroid C-cell tumors in rats in a 2-year study, which is why it carries a boxed warning. It is unknown whether it causes thyroid tumors, including medullary thyroid carcinoma, in humans. It is contraindicated for people with a personal or family history of MTC or MEN 2.

Is tirzepatide nausea worse for weight loss than for diabetes?

Reported GI rates were higher in the obesity trial (SURMOUNT-1, nausea up to about 33%) than in the FDA label’s pooled diabetes trials (nausea up to 18% at 15 mg). These are different populations, and slow titration is designed to limit symptoms in both.

Can tirzepatide cause low blood sugar?

On its own, tirzepatide has a low intrinsic risk of hypoglycemia. The meaningful risk appears when it is combined with insulin or an insulin secretagogue such as a sulfonylurea; a provider may reduce those medications when starting tirzepatide.

What happens if I stop taking tirzepatide?

Weight is often substantially regained after stopping. In the original SURMOUNT-4 trial, mean weight reduction by week 88 was 25.3% with continued tirzepatide versus 9.9% after switching to placebo. In a post hoc analysis of SURMOUNT-4, among participants who had lost at least 10% during the lead-in, 82.5% (254 of 308) of those switched to placebo regained 25% or more of their lost weight by week 88. Decisions about stopping should be made with a provider.

Is compounded tirzepatide the same as Mounjaro or Zepbound?

No. Mounjaro and Zepbound are FDA-approved branded tirzepatide. Compounded tirzepatide is not FDA-approved, is prescription only, and has not been evaluated by the FDA for safety, quality, or efficacy, so it should not be treated as equivalent.